Structure Therapeutics Inc. American Depositary Shares (GPCR) stock price

Structure Therapeutics Inc. American Depositary Shares (GPCR) is a Healthcare · Biotechnology company listed on NASDAQ. Price $34.64 (-1.31%), Market cap $2.62B, 52-week low–high $16.20 ~ $93.79.

Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral small molecule therapeutics to treat various chronic diseases with unmet medical needs in the United States. Its lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, which is in two phase 2 clinical trials for the treatment of obesity, overweight, and related conditions. The company also develops ACCG-2671 and ACCG-3535, an oral small molecule amylin receptor agonist that is in phase1 clinical trial for the treatment of obesity; ANPA-0073, an oral small molecule APJ receptor agonist; and LTSE-2578, an antagonist that t

Key metrics

Financial statements, price targets, institutional (13F) holdings and related news for Structure Therapeutics Inc. American Depositary Shares are updated in real time on BlackAll Trade.

Structure Therapeutics Inc. American Depositary Shares financial summary

Analyst outlook

Key ratios · profitability · growth

Frequently asked questions

What is the current Structure Therapeutics Inc. American Depositary Shares (GPCR) stock price?

Structure Therapeutics Inc. American Depositary Shares trades at $34.64 (-1.31%). Real-time quotes and charts are available on BlackAll Trade.

What is the Structure Therapeutics Inc. American Depositary Shares (GPCR) market cap?

Structure Therapeutics Inc. American Depositary Shares has a market cap of about $2.62B.

What does Structure Therapeutics Inc. American Depositary Shares (GPCR) do?

Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral small molecule therapeutics to treat various chronic diseases with unmet medical needs